1. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity
   Mariarosaria Boccellino et al, 2016, Current Medical Research and Opinion CrossRef
2. Effets indésirables des médicaments anticancéreux utilisés en pneumologie
   G. Camus et al, 2013, Revue des Maladies Respiratoires Actualités CrossRef
3. Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group
   MASAHARU INAGAKI et al, 2016, Molecular and Clinical Oncology CrossRef
4. Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area
   SHINYA SATO et al, 2014, Molecular and Clinical Oncology CrossRef
5. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxol-based Chemotherapy for Stage IV NSCLC
   Tomohiro Tamura et al, 2018, Clinical Lung Cancer CrossRef
6. S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group
   MASAHARU INAGAKI et al, 2016, Molecular and Clinical Oncology CrossRef
7. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
   R. E. Kast, 2015, SpringerPlus CrossRef
8. Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group
   KOICHI KURISHIMA et al, 2013, Molecular and Clinical Oncology CrossRef